Letter to the Editor Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Nov 27, 2024; 16(11): 3632-3635
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3632
Preoperative gastric retention in endoscopic retrograde cholangiopancreatography
Alkiviadis Efthymiou, Department of Gastroenterology, St Luke’s Hospital, Thessaloniki 54623, Greece
Patrick T Kennedy, Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, QMUL, London E1 2AD, United Kingdom
ORCID number: Alkiviadis Efthymiou (0009-0004-6825-3319).
Author contributions: Efthymiou A analyzed the data, reviewed the literature, wrote the original article, and approved the final manuscript; Kennedy PT reviewed and edited the manuscript.
Conflict-of-interest statement: No conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alkiviadis Efthymiou, FEBG, MD, Consultant Gastroenterologist, Department of Gastroenterology, St Luke’s Hospital, Panorama, Thessaloniki 54623, Greece. a_efthimiou@hotmail.com
Received: July 27, 2024
Revised: September 29, 2024
Accepted: October 10, 2024
Published online: November 27, 2024
Processing time: 95 Days and 2.6 Hours

Abstract

We comment on the article by Jia et al, in the World Journal of Gastrointestinal Surgery. We focus mainly on the factors that impair gastric motility and cause gastric retention in the pre-operative setting of endoscopic retrograde cholangiopancreatography (ERCP). ERCP is a complex endoscopic therapeutic procedure, which demands great skill from the endoscopist but also has recognized complications. Gastric retention impairs the endoscopist’s visibility but also increases the risk of complications, such as aspiration pneumonia. Therefore, identifying the factors that predispose to gastric retention alerts the endoscopists of the possible risks and enables them to take evasive action. The authors in the current study by Jia et al developed and validated a predictive model, which incorporates five different factors, i.e., gender, primary disease, jaundice, opioid use, and gastrointestinal obstruction, which were found to influence gastric retention. This model was shown to have a high predictive value to accurately identify patients at risk for gastric retention before a therapeutic ERCP.

Key Words: Gastric retention; Endoscopic retrograde cholangiopancreatography; Predictive model; Malignant gastroparesis

Core Tip: Gastric retention is a relatively common problem prior to endoscopic retrograde cholangiopancreatography (ERCP). In this article, we analyze the factors implicated in gastric retention in ERCP patients, before to their procedure. We also comment on a new predictive model, which can accurately identify patients at greatest risk for gastric retention, thereby helping physicians to avoid complications, unnecessary delays and increased hospital costs.



TO THE EDITOR

Endoscopic retrograde cholangiopancreatography (ERCP) is a complex endoscopic procedure, which is indicated in patents with choledocholithiasis, biliary or pancreatic tumors, chronic pancreatitis, benign biliary strictures, and lesions of the ampulla of Vater. It involves cannulation of the common bile duct (CBD) or in selected cases, the pancreatic duct (PD), with subsequent endoscopic intervention, according to the indication. This might be a sphincterotomy, stone clearance from the CBD, stent insertion to CBD or PD or indeed ampullectomy[1]. Gastric retention refers to the presence of food residue within the stomach due to delayed gastric emptying. It obscures the endoscopic view and consequently might prolong the procedure and thus, increase the potential for complications. Aspiration pneumonia, a recognized complication of gastric retention, can be life-threatening[2]. In their article, Jia et al[3] developed and validated a new prognostic tool, which accurately identifies patients at risk for gastric retention before their procedure.

ERCP AND GASTRIC RETENTION IN THE PRE-OPERATIVE SETTING

Gastric retention is a concern in the context of any upper gastrointestinal endoscopy, and particularly in the case of ERCP. As a complex therapeutic endoscopic procedure, ERCP usually lasts much longer than a diagnostic endoscopy. It requires a clear view of the duodenum and the papilla of Vater in addition to good patient cooperation. Should gastric retention be present, it can obscure the endoscopist’s view, making the procedure more challenging and in some cases impossible. As a result, post-ERCP pancreatitis or aspiration pneumonia are more frequent complications, leading to longer hospital stays, increased morbidity and mortality combined with greater need for medical resources[4]. ERCP is usually performed under deep or conscious sedation in most centers, which means that the patient is not intubated during the procedure. In this setting, if gastric retention is present, the risk of aspiration pneumonia is high. Endoscopists may have to abandon the procedure and re-schedule it after emptying the stomach with a nasogastric tube[5]. This results in delays in the treatment of patients, increased associated costs and a greater burden on the healthcare system. Therefore, the identification of patients with gastric retention before ERCP is of paramount importance, as it will ensure the safety and efficacy of the procedure.

FACTORS THAT CAUSE GASTRIC RETENTION IN ERCP PATIENTS

In their article, Jia et al[3] studied patients with gastric retention before ERCP and analyzed the factors that contribute to delayed gastric emptying. In their retrospective study, they found that gender, primary disease, jaundice, opioid use, and gastrointestinal obstruction were the key factors that influenced preoperative gastric retention in ERCP patients. Based on these factors, they developed and validated a predictive model (PM) that showed a high predictive value. Gastric retention was more frequent in females compared to males. This finding is not surprising, since females suffer more frequently from anxiety and depression, which have been found to alter gastrointestinal motility and cause delayed gastric emptying[6,7]. Moreover, sex hormones, such as estrogens and progesterone have been shown to affect the physiological process of gastric emptying in different animal studies. In particular, estrogens and progesterone at high doses inhibit gastric motility, while progesterone enhances gastric emptying when administered in low doses[8,9].

Biliary or pancreatic tumors may compress adjacent structures, such as the stomach or the duodenum, thereby causing delayed gastric emptying and significant gastric retention. This can also be caused by growth and direct infiltration of the tumor into the gastrointestinal tract, leading to stenosis or complete gastric outlet obstruction. Inflammation of the adjacent mucosa caused by compression of the stomach or duodenum from a tumor can also impair gastric motility and contribute to delayed gastric emptying.

In the setting of malignancy, gastric retention can also occur without actual compression or infiltration of the stomach by the tumor. It may be caused by gastroparesis, referred to as malignant gastroparesis (MG), which may result from the cancer itself or may be a complication of treatment modalities such as surgery, radiation therapy, or chemotherapy. Coexisting conditions, including diabetes, hypothyroidism, and neurologic diseases, may further exacerbate MG. The pathogenesis of MG remains poorly understood. However, potential mechanisms proposed in the literature include post vagotomy syndrome, malignant infiltration of the autonomic nervous system, and paraneoplastic dysmotility with autoantibody-mediated destruction of the enteric nervous system (the interstitial cells of Cajal, also called the intrinsic pacemaker of the gastrointestinal tract, or the myenteric plexus[10].

Jaundice was another factor that negatively influenced gastric emptying. This probably reflects the existence of a biliopancreatic tumor, which simultaneously obstructs the CBD or the hepatic ducts and the gastrointestinal tract.

Opioids are routinely used in patients with biliopancreatic tumors or choledocholithiasis for pain relief due to their potent analgesic effect. However, these drugs also inhibit gastrointestinal motility and may cause nausea, vomiting and constipation, leading to gastric retention in patients scheduled for ERCP[11].

Gastric obstruction can definitely be caused by a biliopancreatic tumor as mentioned before.

PM

In recent years, there has been growing interest in the development of PMs to enhance the effectiveness and safety of different diagnostic and therapeutic procedures. These models aim to provide clinicians with valuable insight and guidance in decision-making, to optimize patient outcomes, and to reduce potential complications. With respect to ERCP, PMs have been employed so far to predict the likelihood of choledocholithiasis, the likelihood of successful bile duct cannulation during ERCP, the risk of post-procedure complications (such as pancreatitis), the presence of malignancies or mortality risk post-ERCP in patients with malignant biliary strictures[12]. Jia et al[3] successfully developed and validated a new PM, which has a high predictive value and accurately identifies patients at risk for gastric retention before a therapeutic ERCP.

This model incorporates five different factors, namely gender, primary disease, jaundice, opioid use, and gastrointestinal obstruction that were found to influence gastric retention in their univariate and multivariate logistic regression analyses. In their study, Jia et al[3] applied first the new model in the training set of patients: Statistical analysis showed that the model had a high predictive ability in identifying preoperative gastric retention in ERCP patients. When the model was applied in the validation set of patients, it showed an impressive predictive performance, with an area under receiver operating characteristic curve of 0.842, a standard error of 0.013, and a 95% confidence interval of 0.8061-0.9216. When the optimal cutoff value was set to 0.56, the sensitivity was slightly lower at 56.2%, but the specificity was as high as 100.0%, further demonstrating the value of the model. Therefore, this PM was proven to have a high predictive value to accurately identify patients at risk for gastric retention before a therapeutic ERCP. If this model is employed in clinical practice by physicians, it will increase the effectiveness and the safety of the procedure: Patients with gastric retention will be readily identified before ERCP and the procedure can be scheduled after prompt clearance of the gastric residue. Should this not be possible, ERCP could be arranged under general anesthesia, thereby avoiding potential complications. In this way, utilization of medical resources will be more efficient, by reducing potential complications, delays and hospital costs.

The study by Jia et al[3] has some limitations. It is a retrospective study and therefore it does not evaluate the new PM prospectively. It will be interesting to see future studies prospectively evaluating the new PM by comparing the outcome of ERCP patients where the PM is employed with the outcome of those where the PM is not utilized. Outcomes would include parameters like post ERCP complications, duration of hospital stay and healthcare costs. Moreover, future studies should also include larger patient numbers than the present study, thereby providing more robust evidence and strengthening the applicability of this new PM.

CONCLUSION

Gender, primary disease, jaundice, opioid use, and gastrointestinal obstruction are factors that influence preoperative gastric retention in ERCP patients. A new PM was established based on these factors, which was proven to have a high predictive value. Physicians who practice ERCP should be aware of these factors, and this recently established PM, in order to easily identify patients at risk for gastric retention. In this way, complications, unnecessary delays and extra hospital costs can be avoided.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: Greece

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Xia L S-Editor: Chen YL L-Editor: A P-Editor: Wang WB

References
1.  Ott DJ, Gilliam JH 3rd, Zagoria RJ, Young GP. Interventional endoscopy of the biliary and pancreatic ducts: current indications and methods. AJR Am J Roentgenol. 1992;158:243-250.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 14]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
2.  Pal P, Ramchandani M. Management of ERCP complications. Best Pract Res Clin Gastroenterol. 2024;69:101897.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Jia Y, Wu HJ, Li T, Liu JB, Fang L, Liu ZM. Establishment of predictive models and determinants of preoperative gastric retention in endoscopic retrograde cholangiopancreatography. World J Gastrointest Surg. 2024;16:2574-2582.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
4.  Buxbaum JL, Freeman M, Amateau SK, Chalhoub JM, Coelho-Prabhu N, Desai M, Elhanafi SE, Forbes N, Fujii-Lau LL, Kohli DR, Kwon RS, Machicado JD, Marya NB, Pawa S, Ruan WH, Sheth SG, Thiruvengadam NR, Thosani NC, Qumseya BJ; (ASGE Standards of Practice Committee Chair). American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations. Gastrointest Endosc. 2023;97:153-162.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 14]  [Reference Citation Analysis (0)]
5.  Azimaraghi O, Bilal M, Amornyotin S, Arain M, Behrends M, Berzin TM, Buxbaum JL, Choice C, Fassbender P, Sawhney MS, Sundar E, Wongtangman K, Leslie K, Eikermann M. Consensus guidelines for the perioperative management of patients undergoing endoscopic retrograde cholangiopancreatography. Br J Anaesth. 2023;130:763-772.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Reference Citation Analysis (0)]
6.  Oshima T. Functional Dyspepsia: Current Understanding and Future Perspective. Digestion. 2024;105:26-33.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
7.  Parker G, Brotchie H. Gender differences in depression. Int Rev Psychiatry. 2010;22:429-436.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 374]  [Cited by in F6Publishing: 405]  [Article Influence: 31.2]  [Reference Citation Analysis (0)]
8.  Chen TS, Doong ML, Chang FY, Lee SD, Wang PS. Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats. Am J Physiol. 1995;268:G171-G176.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 45]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
9.  Liu CY, Chen LB, Liu PY, Xie DP, Wang PS. Effects of progesterone on gastric emptying and intestinal transit in male rats. World J Gastroenterol. 2002;8:338-341.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 35]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
10.  Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007;5:355-363.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Lohse I, Brothers SP. Pathogenesis and Treatment of Pancreatic Cancer Related Pain. Anticancer Res. 2020;40:1789-1796.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 23]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
12.  Lattanzi B, Ramai D, Gkolfakis P, Facciorusso A. Predictive models in EUS/ERCP. Best Pract Res Clin Gastroenterol. 2023;67:101856.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]